Europe Late Stage Chronic Kidney Disease Drugs Market is expected to reach US$ 2,919.58 Mn by 2027

Calcimimetics segment by product type is estimated to lead the market growth during the forecast period

According to a new market research study of “EuropeLate Stage Chronic Kidney Disease Drugs MarketForecast to 2027 - COVID-19 Impact and Analysis by ProductType, Indication, Distribution Channel and Country.” The Europe late stage chronic kidney disease drugs market is expected to reach US$ 2,919.58 million in 2027 from US$ 1,256.98 million in 2019. The market is estimated to grow with a CAGR of 11.3% from 2020 to 2027. The report highlights trends prevailing in the Europe Late Stage Chronic Kidney Disease Drugs Market and the factors driving market along with those that act as hindrances.

Europe late stage chronic kidney disease drugs market,based on product type, has been segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the largest share of the market in 2019, whereas the same segment is anticipated to register the highest CAGR in the market during the forecast period. In late-stage renal disease, kidneys lose their ability to filter waste and excess fluid from blood, which leads to waste accumulation in the body. Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. As per a research study published by the Public Library of Science (PLOS) in April 2020, CKD is estimated to have a prevalence of 2–7% in the adult German population, and the number of people opting for the targeted treatment is expected to increase with rising awareness about this condition. Moreover, the rising prevalence of hypertension and diabetes is a major cause of the progression of end-stage kidney disease (ESKD). These factors are expected to enhance market growth during the forecast period. Also, various strategies put forth by the World Health Organisation (WHO) to help policymakers in developing suitable policies, entailing the vital medicine list concept and the universal health coverage (UHC) approach, would boost the market growth in the coming years.

Key factors that are driving growth of the Europe late stage chronic kidney disease drugs market arehigh prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is likely to hamper the growth of the market during the forecast period.

AbbVie Inc., Amgen and AstraZeneca are among the leading companies operating in the Europelate stage chronic kidney disease drugs market .

The report segments in Europe late stage chronic kidney disease drugs market as follows:

By Product Type

• Calcimimetics
• Vitamin D
• Sterols
• Potassium Binders
• Calcium-Based Phosphate Binders

By Indication

• Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
• Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
• Late Stage Chronic Kidney Disease Induced Hyperkalaemia
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Country

• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe